An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

Archives of General Psychiatry

Volumn 59, Issue 11, 2002, Pages 1021-1026

  Stein, Murray B ^a,d   Goldin, Philippe R ^a,c   Sareen, Jitender ^a,b   Eyler Zorrilla, Lisa T ^a   Brown, Gregory G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c STANFORD UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; AMISULPRIDE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; CIPROFIBRATE; CLOZAPINE; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; INOSITOL NICOTINATE; ISPAGULA; NEUROLEPTIC AGENT; NICOTINIC ACID; OLANZAPINE; OMEGA 3 FATTY ACID; PRAVASTATIN; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; ENGLAND; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; ODDS RATIO; PIRENZEPINE; PRODUCT SURVEILLANCE, POSTMARKETING; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WALES;

EID: 0036840804     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.11.1021     Document Type: Article

References (38)

1. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46:1396-1408.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1991;56:1686-1696.
3. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry. 1997;58:108-111.
4. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44:778-783.
5. Hendersen DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
6. Meyer JM. A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine- and risperidone-treated inpatients [abstract]. Biol Psychiatry. 2001;49:536.
7. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry. 1999;156:1471-1472.
8. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60:767-770.
9. Ghaeli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy. 1999;19:1099-1101.
10. Lieberman JA, Golden R, Stroup S, McEvoy J. Drugs of the psychopharmacological revolution in clinical psychiatry. Psychiatr Serv. 2000;51:1254-1258.
11. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham Study. Ann Intern Med. 1971;74:1-12.
12. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death: The Framingham study. Arch Intern Med. 1981;141:1128-1131.
13. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study. JAMA. 1986;256:2835-2838.
14. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men. Lancet. 1986;2:933-936.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Merkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-749.
17. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369-374.
18. Modal I, Valevski A, Dror S, Weizman A. Serum cholesterol and suicidal tendencies in psychiatric inpatients. J Clin Psychiatry. 1994;55:252-254.
19. Boston PF, Dursun SM, Reveley MA. Cholesterol and mental disorder. Br J Psychiatry. 1996;169:682-689.
20. Boston PF, Dursun SM, Reveley MA. Serum cholesterol and treatment resistance in schizophrenia. Biol Psychiatry. 1996;40:542-543.
21. Saugstad LF, Odegard O. Modality in psychiatric hospitals in Norway 1950-1974. Acta Psychiatr Scand. 1979;59:431-447.
22. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry. 1993;163:183-189.
23. Brown S, Birtwistle J, Poe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. PsycholMed. 1999;29:697-701.
24. Walley T, Mantgani A. The UK general practice research database. Lancet. 1997;350:1097-1099.
25. Lawson DH, Sherman V, Hollowell J, for the Scientific and Ethical Advisory Group. the General practice research database. QJM. 1998;91:445-452.
26. British National Formulary 38. London, England: British Medical Association, Pharmaceutical Society of Great Britain; 1999.
27. Kleinbaum G. Analysis of matched data using logistic regression. In: Logistic Regression: A Self-learning Text. New York, NY: Springer Publishing Co Inc; 1994:60-81.
28. Schaefer EJ. Diagnosis and management of lipoprotein disorders. In: Rifkind BM, ed. Drug Treatment of Hyperlipidemia. New York, NY: Marcel Dekker Inc; 1991:17-52.
29. British Cardiac Society, British Hyperlipidemia Association, and British Hypertension Society. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart. 1998;80(suppl 2):S1-S29.
30. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
31. Grundy MS. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.
32. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35:196-202.
33. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia: A preliminary study. J Clin Hosp Pharm. 1986;11:297-299.
34. Tabata H, Kikuoka M, Kikuoka H, Bessho H, Hirayama J, Hanabusa T, Kubo K, Momotani Y, Sanke T, Nanjo K, Higaehl Y, Miyamura K. Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai. 1987;70(suppl):90-93.
35. Mukherjee S, Decina P, Bocola V, Saracini F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37:68-73.
36. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. SchizophrBull. 1996;22:421-430.
37. Nazareth I, King M, Haines A, Rangel L, Myers S. Accuracy of diagnosis on a general practice computer system. BMJ. 1993;307:32-34.
38. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: Evidence from a national cross sectional survey. BMJ. 2000;321:1322-1325.